Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

NCT05676073 is registered in ClinicalTrials.gov with Shenzhen Kexing Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05676073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05676073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHEN26 Capsule in Patients With Mild to Moderate COVID-19
Lead sponsor
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
December 8, 2022
Completion date
January 27, 2023
Enrollment
91 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19